Article ID Journal Published Year Pages File Type
5700772 European Journal of Surgical Oncology (EJSO) 2017 24 Pages PDF
Abstract
BIA-ALCL is a rare neoplasm with a good prognosis. Our data support the recommendation that stage I disease be managed with surgery alone. Adjuvant chemotherapy may be required for more invasive disease and our experience has shown the efficacy of Brentuximab as a second line treatment.
Related Topics
Health Sciences Medicine and Dentistry Oncology
Authors
, , , , , , , , , , , , , , , , , , ,